Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene : Melanoma Research

Journal Logo

Advanced Search
Short Communications: Clinical Research

Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene

Boileau, Mariea,b,c; Descarpentries, Clotildeb,d; Delzenne, Guillaumea,c; Trentesaux, Victorinea; Greliak, Annaa,b; Jamme, Philippea,b; Marchetti, Philippeb,c,e; Mortier, Laurenta,b

Author Information

aDepartment of Dermatology, Service de Dermatologie, Hôpital C. Huriez, CHU de Lille

bDepartment of Medicine, Université de Lille

cUMR 1172 INSERM, Université de Lille

dDepartment of Biochemistry and Molecular Biology ‘Hormonology Metabolism Nutrition Oncology’, CHU de Lille and

eDepartment of Tissu Bank, Banque de tissus, Centre de biologie et pathologie, CHU de Lille, Lille, France

Received 17 August 2022 Accepted 7 January 2023.

Correspondence to Laurent Mortier, MD, PhD, Department of Dermatology, Hopital Claude Huriez, CHU of Lille, 2 rue Michel Polonowski 59000, France, Tel: +33 320 44 41 93; e-mail: [email protected]

Melanoma Research 33(3):p 247-251, June 2023. | DOI: 10.1097/CMR.0000000000000882

Abstract

Currently, in the absence of BRAFV600 mutation, the management of advanced melanomas is based on immunotherapies, but only half of the patients are responders. RAF1 (also named CRAF) fusions occur in 1–2.1% of wild-type melanomas. Preclinical data suggest that the presence of RAF fusion may be sensitive to MEK inhibitors. We report the case of a patient with an advanced melanoma harboring an EFCC1–RAF1 fusion who showed a clinical benefit from and a partial response to a MEK inhibitor.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid